BLAINJECTIONINJECTABLE
Approved
Jul 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
4/8 — Partial
Xeomin (incobotulinumtoxina) by Merz Therapeutics is acetylcholine release inhibitors [moa]. First approved in 2010.
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Xeomin (incobotulinumtoxinA) is a botulinum toxin type A injection developed by Merz Therapeutics that works by inhibiting acetylcholine release at the neuromuscular junction. It is used to treat various indications where muscle relaxation is therapeutically beneficial. The product represents a purified botulinum toxin formulation without complexing proteins.
$3MPart D
LOE ApproachingWith LOE approaching and modest Part D spending of $3M, the brand team is likely transitioning to defensive strategies and may consolidate roles rather than expand headcount.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
Started Aug 2025
780 enrolled
Chronic Migraine
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Started Aug 2025
990 enrolled
Episodic Migraine
INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)
Started Jun 2022
30 enrolled
Spastic Cerebral Palsy
A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants
Started Jul 2021
45 enrolled
Healthy Participants
A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm
Started Aug 2015
44 enrolled
Cervical DystoniaBlepharospasm
Worked on Xeomin at Merz Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.